EE299 Cost Per PFS-Based Responder for TKI-Naive Patients Receiving Repotrectinib or Entrectinib in ROS1 Fusion Positive Non-Small Cell Lung Cancer (NSCLC) in the United States (US)
Abstract
Authors
Reginald Villacorta Rick Szymialis Yong Yuan Matthew Martin Karissa M. Johnston